Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Invested Capital (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Invested Capital for 16 consecutive years, with $608.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 954.46% year-over-year to $608.4 million, compared with a TTM value of $608.4 million through Dec 2025, up 954.46%, and an annual FY2025 reading of $543.4 million, up 184.42% over the prior year.
  • Invested Capital was $608.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $543.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $749.2 million in Q1 2025 and bottomed at $57.7 million in Q4 2024.
  • Average Invested Capital over 5 years is $412.8 million, with a median of $427.6 million recorded in 2021.
  • The sharpest move saw Invested Capital plummeted 66.78% in 2024, then soared 954.46% in 2025.
  • Year by year, Invested Capital stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then crashed by 56.17% to $173.7 million in 2023, then tumbled by 66.78% to $57.7 million in 2024, then skyrocketed by 954.46% to $608.4 million in 2025.
  • Business Quant data shows Invested Capital for ARWR at $608.4 million in Q4 2025, $543.4 million in Q3 2025, and $559.8 million in Q2 2025.